You just read:

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 11, 2016, 01:00 ET